Bladder Urothelial Carcinoma — Trials

Bladder Urothelial Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

138 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 60
Recruiting: 23
Ph III recruiting: 3
Growth YoY: —
Industry share: 7%
Top sponsor: National Cancer Institute (NCI)
Termination share: 47.6%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (21)

clinicaltrialsPublishedShowing 1–6 of 6 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07667335	Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer	recruiting	Phase 1 / Phase 2	27	Fred Hutchinson Cancer CenterOTHER	1	Sep 17, 2026	clinicaltrials
NCT05833867	Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder Cancer	recruiting	Phase 1	20	Shilpa Gupta, MDOTHER	1	Jul 20, 2026	clinicaltrials